Skip to main content
SpringerLink
Log in

Usefulness of brain 99mTc-TRODAT-1 SPET for the evaluation of Parkinson’s disease

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Nigral dopaminergic projections to the striatum are targeted in Parkinson’s disease (PD). The extent of the degeneration of the dopaminergic system in PD can be visualised by dopamine transporter imaging using single-photon emission tomography (SPET). In this study in 188 patients with PD, we analysed the image patterns and compared them with the clinical features in order to verify the usefulness of technetium-99m TRODAT-1 brain SPET in the evaluation of patients with PD. Two independent readers visually assessed SPET slices from three brain axes according to a “fine” visual scale; results were also grouped according to a “rough” visual scale. Results of both visual and semi-quantitative analyses were compared among patients with different stages of PD and healthy controls. There was good agreement between the readers in the interpretation of the image patterns [kappa statistic (κ)=0.85 for the presence of PD; κ=0.88 for the rough scale and 0.81 for the fine scale]. Good concordance was obtained when visual interpretation was used to evaluate the presence of PD (sensitivity =98%, specificity =86%, κ=0.85). Semi-quantitative analyses revealed significant negative correlations between both striatal and putaminal uptake and disease severity as assessed using the Hoehn and Yahr scale (ρ=−0.89 and −0.93 respectively). An apparent decrease in striatal uptake in early PD, hardly discernible from the uptake level in advanced PD, was commonly found in visual analyses. The results suggest that both visual and semi-quantitative analyses of 99mTc-TRODAT-1 SPET images reflect neurodegeneration in PD, and that 99mTc-TRODAT-1 SPET represents an adequate means for evaluation of the status of patients with PD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1A–C
Fig. 2A–F
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56:33–39.

    CAS  PubMed  Google Scholar 

  2. Hughes AJ, Daniel SE, Kilford L, Lee AJ. The accuracy of clinical diagnosis of idiopathic Parkinson’s disease: A clinicopathological study. J Neurol Neurosurg Psychiatry 1992; 55:181–184.

    CAS  PubMed  Google Scholar 

  3. Agid Y. Parkinson’s disease: pathophysiology. Lancet 1991; 337:1321–1324.

    Article  CAS  PubMed  Google Scholar 

  4. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in striatum of patients with idiopathic Parkinson’s disease N Engl J Med 1988; 876:876–880.

    Google Scholar 

  5. Nirenberg MJ, Vaughan RA, Uhl GR, Kuhar MJ, Pickel VM. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J Neurosci 1996; 16:436–447.

    CAS  PubMed  Google Scholar 

  6. Chen YK, Liu LS, Huang WS, et al. The role of dopamine transporter imaging agent [99mTc]TRODAT-1 in hemi-parkinsonism rat brain. Nucl Med Biol 2001; 28:923–928.

    Article  CAS  PubMed  Google Scholar 

  7. Wilson JM, Levey AI, Rajput A, et al. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson’s disease. Neurology 1996; 47:718–726.

    CAS  PubMed  Google Scholar 

  8. Mosley PD, Schneider JS, Acton PD, et al. Binding of99mTc-TRODAT-1 to dopamine transporter in patients with Parkinson’s disease and in healthy volunteers. J Nucl Med 2000; 41:584–589.

    CAS  PubMed  Google Scholar 

  9. Niznik HB, Fogel EF, Fassos FF, Seeman P. The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus. J Neurochem 1991; 56:192–198.

    CAS  PubMed  Google Scholar 

  10. Brooks DJ. PET studies on the early and differential diagnosis of Parkinson’s disease. Neurology 1993; 43 (Suppl 6):S6–S16.

    Google Scholar 

  11. Booij J, Tissingh G, Winogrodzka A, van Royen EZ. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med 1999; 26:171–182.

    Article  CAS  PubMed  Google Scholar 

  12. Innis RB, Seibyl JB, Scanley BE, et al. Single photon computed imaging demonstrates loss of striatal dopamine transporters in Parkinson’s disease. Proc Natl Acad Sci U S A 1993; 90:11965–11969.

    CAS  PubMed  Google Scholar 

  13. Seibyl JP, Marek KL, Quinlan D, et al. Decreased single-photon emission tomographic [123I]β-CIT SPECT striatal uptake correlates with symptom severity in Parkinson’s disease. Ann Neurol 1995; 38:589–598.

    Google Scholar 

  14. Marek KL, Seibyl JP, Zoghbi SS, et al. [123I]β-CIT SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson’s disease. Neurology 1996; 46:231–237.

    CAS  PubMed  Google Scholar 

  15. Staffen W, Mair A, Unterrainer J, Trinka E, Bsteh C, Ladurner G. [123I]β-CIT binding and SPET compared with clinical diagnosis in parkinsonism. Nucl Med Commun 2000; 21: 417–424.

    Article  CAS  PubMed  Google Scholar 

  16. Kung MP, Stevenson DA, Plossl K, et al. [99mTc]TRODAT-1: a novel technetium-99m complex as dopamine transporter imaging agent. Eur J Nucl Med 1997; 24:372–380.

    Article  CAS  PubMed  Google Scholar 

  17. Huang WS, Lin SZ, Lin JC, Wey SP, Ting G, Liu RS. Evaluation of early-stage Parkinson’s disease with99mTc-TRODAT-1 imaging. J Nucl Med 2001; 42:1303–1308.

    CAS  PubMed  Google Scholar 

  18. Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson’s disease. Ann Neurol 1992; 32:S125–S127.

    PubMed  Google Scholar 

  19. Hoehn MW, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology (Minneap) 1967; 17:427–442.

    Google Scholar 

  20. Wey SP, Tsai HY, Jong JS, et al. Formulation of a lyophilized kit for preparation of [99mTc]TRODAT-1 [abstract]. Eur J Nucl Med 1998; 25 (Suppl):1164.

    Google Scholar 

  21. Chou YH, Lu RB, Huang WS, Wey SP, Ding G. Dopamine transporter binding and cognitive function in methamphetamine abuser during detoxification: a SPECT study. J Cereb Blood Flow Metab 2003; 23 (Suppl):8.

    Google Scholar 

  22. Snedecor GW, Cochran WG. Specific indices of interrater reliability. In: Snedecor GW, Cochran WG, eds. Statistical methods, 6th edn. Ames, IO: Iowa State University Press; 1996:200–205.

  23. Fleiss JL. Statistical methods for rates and proportions, 2nd edn. New York: John Wiley; 1981:218.

  24. Parkinson Study Group. A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Neurology 2000; 55:1540–1547.

    PubMed  Google Scholar 

  25. Tatsch K. Can SPECT imaging of dopamine uptake sites replace PET imaging in Parkinson’s disease? Eur J Nucl Med Mol Imaging 2002; 29:711–714.

    Article  PubMed  Google Scholar 

  26. Løkkegarrd A, Werdelin LM, Friberg L. Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand. Eur J Nucl Med Mol Imaging 2002; 29:1623–1629.

    Article  PubMed  Google Scholar 

  27. Catafau AM. Brain SPECT of dopaminergic neurotransmission: a new tool with proved clinical impact. Nucl Med Commun 2001; 22:1059–1060.

    Article  CAS  PubMed  Google Scholar 

  28. Eising EG, Muler T, Freudenberg L, et al. SPECT imaging with [123I]-β-CIT in Parkinsonism: comparison of SPECT images obtained by a single headed and a three-headed gamma camera. Nucl Med Commun 2001; 22:145–150.

    Article  CAS  PubMed  Google Scholar 

  29. Muller TH, Farahati J, Kuhn W, et al. [123I]β-CIT SPECT visualizes dopamine transporters loss in de novo parkinsonian patients. Eur Neurol 1998; 39:44–48.

    Article  CAS  PubMed  Google Scholar 

  30. Brooks DJ. Functional imaging in relation to parkinsonian syndromes. J Neurol Sci 1993; 115:1–17.

    Article  CAS  PubMed  Google Scholar 

  31. van Dyck CH, Seibyl JP, Malison RT, et al. Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriatr Psychiatry 2002; 10:36–43.

    PubMed  Google Scholar 

  32. King MA, Schwinger RB, Penney BC, Doherty PW, Bianco JA. Digital restoration of indium-111 and iodine-123 SPECT images with optimized Metz filters. J Nucl Med 1986; 27:1327–1336.

    CAS  PubMed  Google Scholar 

  33. Kuikka JT, Bergström, Ahonen A, Länsimies E. The dosimetry of iodine-123 labelled 2β-carbomethoxy-3β-(4-iodophenyl)tropane. Eur J Nucl Med 1994; 21:53–56.

    CAS  PubMed  Google Scholar 

  34. Vilkow ND, Fowler JS, Wang GJ, et al. Decreased dopamine transporters with age in healthy human subjects. Ann Neurol 1994; 36:237–239.

    Google Scholar 

  35. Mozley PD, Acton PD, Barraclough ED, et al. Effects of age on dopamine transporters in healthy humans. J Nucl Med 1999; 40:1812–1817.

    CAS  PubMed  Google Scholar 

  36. Marek K, Innis R, Van Dyck C, et al. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression. Neurology 2001; 57:2089–2094.

    CAS  PubMed  Google Scholar 

  37. Dressel SHJ, Kung MP, Plössl K, Meegalla SK, Kung HF. Pharmacological effects of dopaminergic drugs on in vivo binding of [99mTc]TRODAT-1 to the central dopamine transporter in rats. Eur J Nucl Med 1998; 25:31–39.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Tri-Service General Hospital, 325 Cheng-Kung Road, Section 2, 114, Neihu, Taipei, Taiwan, R.O.C.

    Wen-Sheng Huang & Yu-Wen Yang

  2. School of Public Health, National Defense Medical Center, Taipei, Taiwan, R.O.C.

    Meei-Shyuan Lee

  3. Department of Neurology, Tri-Service General Hospital, Taipei, Taiwan, R.O.C.

    Jiann-Chyun Lin

  4. Department of Radiology, Tri-Service General Hospital, Taipei, Taiwan, R.O.C.

    Cheng-Yu Chen

  5. Department of Neurosurgery, Tzu-Chi Medical Center, Fa-Lian, Taiwan, R.O.C.

    Shinn-Zong Lin

  6. Institute of Nuclear Energy Research, Lung-Tan, Taiwan, R.O.C.

    Shiaw-Pyng Wey

  7. School of Medical Technology, Chang Gung University, Taoyuan, Taiwan, R.O.C.

    Shiaw-Pyng Wey

Authors
  1. Wen-Sheng Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Meei-Shyuan Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jiann-Chyun Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cheng-Yu Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yu-Wen Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shinn-Zong Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shiaw-Pyng Wey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wen-Sheng Huang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huang, WS., Lee, MS., Lin, JC. et al. Usefulness of brain 99mTc-TRODAT-1 SPET for the evaluation of Parkinson’s disease. Eur J Nucl Med Mol Imaging 31, 155–161 (2004). https://doi.org/10.1007/s00259-003-1331-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-003-1331-x

Keywords

Search

Navigation